AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2013
Dec 3, 2013
33422_dirs_2013-12-03_a4432f2e-a5e3-4b6f-b08d-9d215eff6cbf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2013-12-02
Reporting Person: MAULDIN JOHN F (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-12-02 | Common Stock | P | 609 | $8.1967 | Acquired | 17456 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4947 | Indirect |
Footnotes
F1: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2013.
F2: Reflects weighted average price. Range of prices were between $8.19 and $8.20. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21